A Phase I Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- or Second-line Treatment
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan; Oxaliplatin
- Indications Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer
- Focus Adverse reactions
- Acronyms SIRINOX
- Sponsors Nordic Group
- 16 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2020.
- 16 Aug 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
- 17 Mar 2015 New trial record